Education
About Us
Working with TipRanks
Follow Us
Actuate Therapeutics, Inc. (ACTU)
NASDAQ:ACTU
ACTU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.51 - $11.73
Previous CloseN/A
Volume10.16K
Average Volume (3M)35.28K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.20
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding19,531,635
10 Day Avg. Volume32,276
30 Day Avg. Volume35,280
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$20.00Price Target Upside181.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
ACTU FAQ
What was Actuate Therapeutics, Inc.’s price range in the past 12 months?
Actuate Therapeutics, Inc. lowest stock price was $5.51 and its highest was $11.73 in the past 12 months.
What is Actuate Therapeutics, Inc.’s market cap?
Currently, no data Available
When is Actuate Therapeutics, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Actuate Therapeutics, Inc.’s earnings last quarter?
Currently, no data Available
Is Actuate Therapeutics, Inc. overvalued?
According to Wall Street analysts Actuate Therapeutics, Inc.’s price is currently Undervalued.
Does Actuate Therapeutics, Inc. pay dividends?
Actuate Therapeutics, Inc. does not currently pay dividends.
What is Actuate Therapeutics, Inc.’s EPS estimate?
Actuate Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actuate Therapeutics, Inc. have?
Actuate Therapeutics, Inc. has 19,531,635 shares outstanding.
What happened to Actuate Therapeutics, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Actuate Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACTU
---
Company Description
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
---
ACTU Stock 12 Month Forecast
Average Price Target
$20.00
▲(181.29% Upside)
Technical Analysis
Biodexa Pharmaceuticals
―
Applied DNA Sciences
―
Salarius Pharmaceuticals
―
Hepion Pharmaceuticals
―
ZyVersa Therapeutics
―
Best Analysts Covering ACTU
1 Year
1 Year Success Rate
1/1 ratings generated profit
1 Year Average Return
+3.50%
initiated a buy rating 27 days ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +3.50% per trade.
---